Onchodermatitis

Current Opinion in Infectious Diseases

Volumn 23, Issue 2, 2010, Pages 124-131

  Murdoch, Michele E ^a  

^a WATFORD GENERAL HOSPITAL   (United Kingdom)

Author keywords

African Programme for Onchocerciasis Control; Ivermectin; Onchocercal skin disease; Onchocerciasis; Onchodermatitis

Indexed keywords

AZITHROMYCIN; DOXYCYCLINE; IVERMECTIN; MOXIDECTIN; RIFAMPICIN;

AFRICA; COLOMBIA; ENDEMIC DISEASE; ENDOSYMBIOSIS; HUMAN; IMMUNOPATHOGENESIS; ONCHOCERCIASIS; ONCHODERMATITIS; PARASITE TRANSMISSION; PATCH TEST; REVIEW; SINGLE DRUG DOSE; SOUTH AND CENTRAL AMERICA; VECTOR CONTROL; WOLBACHIA;

AFRICA; ANIMALS; ANTI-BACTERIAL AGENTS; DERMATITIS; DOXYCYCLINE; FILARICIDES; HUMANS; INSECT CONTROL; IVERMECTIN; LATIN AMERICA; MACROLIDES; ONCHOCERCIASIS; SKIN DISEASES, PARASITIC;

EID: 77649250566     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e328336a256     Document Type: Review

References (81)

1. Basanez MG, Pion SD, Churcher TS, et al. River blindness: a success story under threat? PLoS Med 2006; 3:e371; doi:10.1371/journal.pmed. 0030371.
2. WHO. Meeting of the International Task Force for Disease Eradication 11 January 2007. Wkly Epidemiol Rec 82, 2007. pp. 197-208.
3. WHO Expert Committee on Onchocerciasis. Third report. World Health Organ Tech Rep Ser 1987; 752:1-167.
4. Amazigo U, Noma M, Bump J, Liese Beal. Onchocerciasis (chapter 15). In: Disease and mortality in sub-Saharan Africa. Jamieson DT, Feachem RG, Makgoba MW, et al. editors. World Bank, Washington (DC): World Bank (Second); 2006. pp. 215-222.
5. Njepuome NA, Hopkins DR, Richards FO Jr, et al. Nigeria's war on terror: fighting dracunculiasis, onchocerciasis, lymphatic filariasis, and schistoso-miasis at the grassroots. Am J Trop Med Hyg 2009; 80:691-698.
6. Hougard JM, Alley ES, Yameogo L, et al. Eliminating onchocerciasis after 14 years of vector control: a proved strategy. J Infect Dis 2001; 184:497-503.
7. Aziz MA, Diallo S, Diop IM, et al. Efficacy and tolerance of ivermectin in human onchocerciasis. Lancet 1982; 2:171-173.
8. Thylefors B. The Mectizan Donation Program (MDP). Ann Trop Med Parasitol 2008; 102 (Suppl 1):39-44.
9. Murdoch ME, Hay RJ, Mackenzie CD, et al. A clinical classification and grading system of the cutaneous changes in onchocerciasis. Br J Dermatol 1993; 129:260-269.
10. Brieger WR, Ososanya OO, Kale OO, et al. Gender and ethnic differences in onchocercal skin disease in Oyo State, Nigeria. Trop Med Int Health 1997; 2:529-534.
11. Kipp W, Bamhuhiiga J. Onchodermal skin disease in a hyperendemic onchocerciasis focus in western Uganda. Am J Trop Med Hyg 2002; 67:475-479.
12. Murdoch ME, Asuzu MC, Hagan M, et al. Onchocerciasis: the clinical and epidemiological burden of skin disease in Africa. Ann Trop Med Parasitol 2002; 96:283-296.
13. Brieger WR, Awedoba AK, Eneanya CI, et al. The effects of ivermectin on onchocercal skin disease and severe itching: results of a multicentre trial. Trop Med Int Health 1998; 3:951-961.
14. Brieger WR, Oshiname FO, Ososanya OO. Stigma associated with onchocercal skin disease among those affected near the Ofiki and Oyan Rivers in western Nigeria. Soc Sci Med 1998; 47:841-852.
15. Vlassoff C, Weiss M, Ovuga EB, et al. Gender and the stigma of onchocercal skin disease in Africa. Soc Sci Med 2000; 50:1353-1368.
16. OladepoO, Brieger WR, OtusanyaS, etal. Farm land size and onchocerciasis status of peasant farmers in south-western Nigeria. Trop Med Int Health 1997; 2:334-340.
17. Murdoch ME, Abiose A, Garate T, et al. Human onchocerciasis in Nigeria: isotypic responses and antigen recognition in individuals with defined cutaneous pathology. Am J Trop Med Hyg 1996; 54:600-612.
18. Ali MM, Baraka OZ, AbdelRahman SI, et al. Immune responses directed against microfilariae correlate with severity of clinical onchodermatitis and treatment history. J Infect Dis 2003; 187:714-717.
19. Murdoch ME, Payton A, Abiose A, et al. HLA-DQ alleles associate with cutaneous features of onchocerciasis. The Kaduna-London-Manchester Collaboration for Research on Onchocerciasis. Hum Immunol 1997; 55:46-52.
20. Hay RJ, Mackenzie CD, Guderian R, et al. Onchodermatitis: correlation between skin disease and parasitic load in an endemic focus in Ecuador. Br J Dermatol 1989; 121:187-198.
21. Elson LH, Days A, Calvopina M, et al. In utero exposure to Onchocerca volvulus: relationship to subsequent infection intensity and cellular immune responsiveness. Infect Immun 1996; 64:5061-5065.
22. Bari AU. Clinical spectrum of onchodermatitis. J Coll Physicians Surg Pak 2007; 17:453-456.
23. Glover M, Murdoch M, Leigh I. Subtle early features of onchocerciasis in a European. J R Soc Med 1991; 84:435.
24. Ezzedine K, Malvy D, Dhaussy I, etal. Onchocerciasis-associated limb swelling in a traveler returning from Cameroon. J Travel Med 2006; 13:50-53.
25. Albert MR, Klion A, Turner ML. Pruritus and eosinophilia in a 14-year-old girl from Liberia. J Am Acad Dermatol 2001; 45:435-437.
26. Niamba P, Gaulier A, Taieb A. Hanging groin and persistent pruritus in a patient from Burkina Faso. Int J Dermatol 2007; 46:485-486.
27. Amazigo U. Onchocerciasis and women's reproductive health: indigenous and biomedical concepts. Trop Doct 1993; 23:149-151.
28. Amazigo UO. Detrimental effects of onchocerciasis on marriage age and breast-feeding. Trop Geogr Med 1994; 46:322-325.
29. Hotez PJ, Kamath A. Neglected tropical diseases in sub-saharan Africa: review of their prevalence, distribution, and disease burden. PLoS Negl Trop Dis 2009; 3:e412; doi:10.1371/journal.pntd.0000412
30. TDR. New light shed on the importance and care of onchcercal skin disease. TDR. News 1998; 55:5
31. TDR. Methods for community diagnosis of onchocerciasis to guide ivermec-tin-based control in Africa. Geneva: World Health Organization; 1992.
32. Remme JHF. The global burden of onchocerciasis in 1990. Geneva: World Health Organization; 2004 http.//www.who.int/healthinfo/statistics/bod- onchocercaisis1990.pdf.
33. Boatin BA, Richards FO Jr. Control of onchocerciasis. Adv Parasitol 2006; 61:349-394.
34. Ngoumou P, Walsh JF, Mace JM. A rapid mapping technique for the prevalence and distribution of onchocerciasis: a Cameroon case study. Ann Trop Med Parasitol 1994; 88:463-474.
35. Noma M, Nwoke BE, Nutall I, et al. Rapid epidemiological mapping of onchocerciasis (REMO): its application by the African Programme for Onchocerciasis Control (APOC). Ann Trop Med Parasitol 2002; 96 (Suppl 1): S29-S39.
36. TDR (UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases). Guidelines for analysis for REMO data using GIS. Geneva: World Health Organization; 1998.
37. Brattig NW, Lepping B, Timmann C, et al. Onchocerca volvulus-exposed persons fail to produce interferon-gamma in response to O. volvulus antigen but mount proliferative responses with interleukin-5 and IL-13 production that decrease with increasing microfilarial density. J Infect Dis 2002; 185:1148-1154.
38. Timmann C, Abraha RS, Hamelmann C, et al. Cutaneous pathology in onchocerciasis associated with pronounced systemic T-helper 2-type responses to Onchocerca volvulus. Br J Dermatol 2003; 149:782-787.
39. Saint Andre A, Blackwell NM, Hall LR, et al. The role of endosymbiotic Wolbachia bacteria in the pathogenesis of river blindness. Science 2002; 295:1892-1895.
40. Maizels RM, Lawrence RA. Immunological tolerance: the key feature in human filariasis? Parasitol Today 1991; 7:271-276.
41. Satoguina J, Mempel M, Larbi J, et al. Antigen-specific T regulatory-1 cells are associated with immunosuppression in a chronic helminth infection (onchocerciasis). Microbes Infect 2002; 4:1291-1300.
42. Satoguina JS, Adjobimey T, Arndts K, et al. Tr1 and naturally occurring regulatory T cells induce IgG4 in B cells through GITR/GITR-L interaction, IL-10 and TGF-beta. Eur J Immunol 2008; 38:3101-3113.
43. Brattig NW, Schwohl A, Rickert R, Buttner DW. The filarial parasite Onchocerca volvulus generates the lipid mediator prostaglandin E(2). Microbes Infect 2006; 8:873-879.
44. Korten S, Badusche M, Buttner DW, etal. Natural death of adult Onchocerca volvulus and filaricidal effects of doxycycline induce local FOXP3+/CD4+ regulatory T cells and granzyme expression. Microbes Infect 2008; 10:313-324.
45. Erttmann KD, Buttner DW. Immunohistological studies on Onchocerca volvulus paramyosin. Parasitol Res 2009; 105:1371-1374.
46. Liebau E, Hoppner J, Muhlmeister M, et al. The secretory omega-class glutathione transferase OvGST3 from the human pathogenic parasite Onchocerca volvulus. FEBS J 2008; 275:3438-3453.
47. Ali MM, Elghazali G, Montgomery SM, et al. Fc gamma RIIa (CD32) polymorphism and onchocercal skin disease: implications for the development of severe reactive onchodermatitis (ROD). Am J Trop Med Hyg 2007; 77: 1074-1078.
48. Timmann C, van der KE, Kleensang A, et al. Human genetic resistance to Onchocerca volvulus: evidence for linkage to chromosome 2p from an autosome-wide scan. J Infect Dis 2008; 198:427-433.
49. Mweya CN, Kalinga AK, Kabula B, et al. Onchocerciasis situation in the Tukuyu focus of southwest Tanzania after ten years of ivermectin mass treatment. Tanzan Health Res Bull 2007; 9:174-179.
50. Boatin BA, Toe L, Alley ES, et al. Detection of Onchocerca volvulus infection in low prevalence areas: a comparison of three diagnostic methods. Parasitology 2002; 125:545-552.
51. Ozoh G, Boussinesq M, BissekAC, etal. Evaluation ofthediethylcarbamazine patch to evaluate onchocerciasis endemicity in Central Africa. Trop Med Int Health 2007; 12:123-129.
52. Park J, Dickerson TJ, Janda KD. Major sperm protein as a diagnostic antigen for onchocerciasis. Bioorg Med Chem 2008; 16:7206-7209.
53. Ayong LS, Tume CB, Wembe FE, et al. Development and evaluation of an antigen detection dipstick assay for the diagnosis of human onchocerciasis. Trop Med Int Health 2005; 10:228-233.
54. Burbelo PD, Leahy HP, Iadarola MJ, Nutman TB. A four-antigen mixture for rapid assessment of Onchocerca volvulus infection. PLoS Negl Trop Dis 2009; 3:e438; doi:10.1371/journal.pntd.0000438.
55. Hoerauf A. Filariasis: new drugs and new opportunities for lymphatic filariasis and onchocerciasis. Curr Opin Infect Dis 2008; 21:673-681.
56. Rodriguez-Perez MA, Lutzow-Steiner MA, Segura-Cabrera A, et al. Rapid suppression of Onchocerca volvulus transmission in two communities of the Southern Chiapas focus, Mexico, achieved by quarterly treatments with Mectizan. Am J Trop Med Hyg 2008; 79:239-244.
57. Awadzi K, Boakye DA, Edwards G, et al. An investigation of persistent microfilaridermias despite multiple treatments with ivermectin, in two onch-ocerciasis-endemic foci in Ghana. Ann Trop Med Parasitol 2004; 98:231-249. (Pubitemid 38594732)
58. Taylor MJ, Awadzi K, Basanez MG, et al. Onchocerciasis control: vision for the future from a Ghanian perspective. Parasit Vectors 2009; 2:7; doi:10.1186/1756-3305-2-7.
59. Churcher TS, Pion SD, Osei-Atweneboana MY, et al. Identifying sub-optimal responses to ivermectin in the treatment of river blindness. Proc Natl Acad Sci USA 2009; 106:16716-16721.
60. Bourguinat C, Pion SDS, Kamgno J, et al. Genetic selection of low fertile Onchocerca volvulus by ivermectin treatment. PLoS Negl Trop Dis 2007: 1(1): e72. doi:10.1371/journal.pntd.0000072. (Pubitemid 352024669)
61. Churcher TS, Basanez MG. Sampling strategies to detect anthelmintic resistance: the perspective of human onchocerciasis. Trends Parasitol 2009; 25:11-17.
62. Hoerauf A, Specht S, Buttner M, et al. Wolbachia endobacteria depletion by doxycycline as antifilarial therapy has macrofilaricidal activity in onchocercia sis: a randomized placebo-controlled study. Med Microbiol Immunol 2008; 197:295-311.
63. Wanji S, Tendongfor N, Nji T, et al. Community-directed delivery of doxycycline for the treatment of onchocerciasis in areas of co-endemicity with loiasis in Cameroon. Parasit Vectors 2009; 2:39; doi:10.11 86/1756-3305-2-39.
64. Richards FO Jr, Amann J, Arana B, et al. No depletion of Wolbachia from Onchocerca volvulus after a short course of rifampin and/or azithromycin. Am J Trop Med Hyg 2007; 77:878-882.
65. Specht S, Mand S, Marfo-Debrekyei Y, et al. Efficacy of 2-and 4-week rifampicin treatment on the Wolbachia of Onchocerca volvulus. Parasitol Res 2008; 103:1303-1309.
66. Hoerauf A, Marfo-Debrekyei Y, Buttner M, et al. Effects of 6-week azithromycin treatment on the Wolbachia endobacteria of Onchocerca volvulus. Parasitol Res 2008; 103:279-286.
67. Wu B, Novelli J, Foster J, et al. The heme biosynthetic pathway of the obligate Wolbachia endosymbiont of Brugia malayi as a potential antifilarial drug target. PLoS Negl Trop Dis 2009; 3:e475; doi:10.1371/journal.pntd. 0000475
68. TDR. New drug that could dramatically speed up the elimination of river blindness across Africa begins clincial trial. WHO. 9 A.D. 2-11-10009 Bangoura O.The World Bank. Ann Trop Med Parasitol 2008; 102 (Suppl 1): 31-33.
69. Sauerbrey M. The Onchocerciasis Elimination Program for the Americas (OEPA). Ann Trop Med Parasitol 2008; 102 (Suppl 1):25-29.
70. African Programme for Onchocerciasis Control: report on taskforce meeting, July 2008. Wkly Epidemiol Rec 2008; 83:307-312.
71. Wakabi W. Worrisome outbreak of river blindness in northern Uganda. CMAJ 2009; 181:E4; doi:10.1503/cmaj.090821.
72. Boakye DA, Fokam E, Ghansah A, et al. Cardiocladius oliffi (Diptera: Chir-onomidae) as a potential biological control agent against Simulium squamosum (Diptera: Simuliidae). Parasit Vectors 2009; 2:20; doi:10.11 86/1756-3305-2-20.
73. Okeibunor JC, Ogungbemi MK, Sama M, et al. Additional health and development activities for community-directed distributors of ivermectin: threat or opportunity for onchocerciasis control? Trop Med Int Health 2004; 9:887-896.
74. Kisinza WN, Kisoka WJ, Mutalemwa PP, et al. Community directed interventions for malaria, tuberculosis and vitamin A in onchocerciasis endemic districts of Tanzania. Tanzan J Health Res 2008; 10:232-239.
75. Homeida M, Braide E, Elhassan E, et al. APOC's strategy of community-directed treatment with ivermectin (CDTI) and its potential for providing additional health services to the poorest populations. Ann Trop Med Parasitol 2009; 96:93-104.
76. Ndyomugyenyi R, Tukesiga E, Katamanywa J. Intermittent preventive treatment of malaria in pregnancy (IPTp): participation of community-directed distributors of ivermectin for onchocerciasis improves IPTp access in Ugandan rural communities. Trans R Soc Trop Med Hyg 2009; 103:1221-1228.
77. Onchocerciasis (river blindness). Report from the eighteenth InterAmerican Conference on Onchocerciasis, November 2008. Wkly Epidemiol Rec 2009; 84:385-389.
78. Banic DM, Calvao-Brito RH, Marchon-Silva V, et al. Impact of 3 years ivermectin treatment on onchocerciasis in Yanomami communities in the Brazilian Amazon. Acta Trop 2009; 112:125-130.
79. Diawara L, Traore MO, Badji A, et al. Feasibility of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: first evidence from studies in Mali and Senegal. PLoS Negl Trop Dis 2009; 3:e497; doi:10.1371/
80. Traore S, Wilson MD, Sima A, et al. The elimination of the onchocerciasis vector from the island of Bioko as a result of larviciding by the WHO African Programme for Onchocerciasis Control. Acta Trop 2009; 111:211-218.
81. Garms R, Lakwo TL, Ndyomugyenyi R, et al. The elimination of the vector Simulium neavei from the Itwara onchocerciasis focus in Uganda by ground larviciding. Acta Trop 2009; 111:203-210.